Linear lipoatrophy following intra ‐articular triamcinolone acetonide injection mimicking linear scleroderma

AbstractA 12 ‐year‐old female with oligoarticular juvenile inflammatory arthritis developed an atrophic linear plaque involving the left medial forearm and proximal arm 7 months after intra‐articular triamcinolone injection for arthritis. The plaque spontaneously resolved without treatment over approximat ely one year. It is important to recognize this rare complication of intra‐articular steroid injection in order to avoid potential misdiagnosis as linear scleroderma and subsequent immunosuppressive treatment.
Source: Pediatric Dermatology - Category: Dermatology Authors: Tags: BRIEF REPORT Source Type: research

Related Links:

A proportion of patients with fibrosing interstitial lung diseases (ILDs) develop a progressive phenotype characterised by decline in lung function, worsening quality of life and early mortality. Other than idiopathic pulmonary fibrosis (IPF), there are no approved drugs for fibrosing ILDs and a poor evidence base to support current treatments. Fibrosing ILDs with a progressive phenotype show commonalities in clinical behaviour and in the pathogenic mechanisms that drive disease worsening. Nintedanib is an intracellular inhibitor of tyrosine kinases that has been approved for treatment of IPF and has recently been shown to...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Review Source Type: research
AbstractWe sought to determine the prevalence of additional connective tissue diseases (CTDs) in patients with idiopathic inflammatory myopathies (IIM), and to study the muscle biopsy patterns in various clinico-serologic subsets of myositis. We undertook a retrospective cohort study of 648 patients with a histological diagnosis of IIM. The following was determined from the South Australian Myositis Database: presence of associated CTDs, histological details and presence of myositis-specific (MSA) or myositis-associated (MAA) antibodies. Among patients with IIM, a significantly greater proportion had systemic sclerosis 32/...
Source: Rheumatology International - Category: Rheumatology Source Type: research
Publication date: Available online 11 September 2019Source: Best Practice &Research Clinical Endocrinology &MetabolismAuthor(s): Vânia Vieira Borba, Gisele Zandman-Goddard, Yehuda ShoenfeldAbstractNowadays, more than 80 autoimmune disorders are recognized, in which an aberrant immune response against different organs and tissues plays a crucial role. Hormonal homeostasis has great influence in achieving competent and healthy immune system function. Prolactin has a bioactive function acting as a hormone and a cytokine. It influences the immune system modulation, mainly inhibiting the negative selection of auto...
Source: Best Practice and Research Clinical Endocrinology and Metabolism - Category: Endocrinology Source Type: research
ConclusionPSGL ‐1 absence induces reduction of Treg, NO production and ERα expression and the increase of Angiotensin II in the lungs of female mice, favoring the development of PAH
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: FULL LENGTH Source Type: research
ObjectiveTo assess the preclinical efficacy and mechanism of action of an anti ‐CX3CL1 monoclonal antibody (mAb) in systemic sclerosis (SSc).MethodsCultured human dermal fibroblasts were used to evaluate the direct effect of anti ‐CX3CL1 mAb on fibroblasts. In addition, bleomycin ‐induced and growth factor–induced models of SSc were used to investigate the effect of anti‐CX3CL1 mAb on leukocyte infiltration, collagen deposition, and vascular damage in the skin.ResultsAnti ‐CX3CL1 mAb treatment significantly inhibited Smad3 phosphorylation (P
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: Original Article Source Type: research
Title: FDA Approves First Treatment for ILD With Systemic Sclerosis, SclerodermaCategory: Health NewsCreated: 9/10/2019 12:00:00 AMLast Editorial Review: 9/10/2019 12:00:00 AM
Source: MedicineNet Arthritis General - Category: Rheumatology Source Type: news
Arthritis&Rheumatology, EarlyView.
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: Editorial Source Type: research
Conclusions: Rituximab is both safe and effective for the treatment of acquired angioedema with C1-inhibitor deficiency, ANCA-associated vasculitis, autoimmune hemolytic anemia, Behçet’s disease, bullous pemphigoid, Castleman’s disease, cryoglobulinemia, Goodpasture’s disease, IgG4-related disease, immune thrombocytopenia, juvenile idiopathic arthritis, membraneous nephropathy, relapsing-remitting multiple sclerosis, myasthenia gravis, nephrotic syndrome, neuromyelitis optica, pemphigus, rheumatoid arthritis, spondyloarthropathy, and systemic sclerosis. Conversely, rituximab failed to show an effec...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
AbstractRheumatoid arthritis (RA) is a systemic, autoimmune disease that affects joints and extra-articular structures. In the last decade, the management of this chronic disease has dramatically changed with the introduction of several targeted mechanisms of action, such as tumor necrosis factor- α inhibition, T-cell costimulation inhibition, B-cell depletion, interleukin-6 blockade, and Janus kinase inhibition. Beyond its well-known hematopoietic role on the proliferation and differentiation of myeloid cells, granulocyte-monocyte colony-stimulating factor (GM-CSF) is a proinflammatory medi ator acting as a cytokine...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
To determine the effect of riociguat, an oral, selective soluble guanylate cyclase stimulator, on the net digital ulcer (DU) burden in systemic sclerosis (SSc).
Source: Arthritis Research and Therapy - Category: Rheumatology Authors: Tags: Research article Source Type: research
More News: Arthritis | Dermatology | Pediatrics | Rheumatology | Scleroderma | Skin | Triamcinolone